Crunchfish patents device-agnostic trusted client applications for offline use cases

Crunchfish AB (“Crunchfish”) has applied for a strategically important and broad patent, protecting the use of device-agnostic trusted client applications for offline use cases in any mobile client / server system. There are multiple market segments where

Sammanhang: ...There are multiple market segments where device-agnostic trusted client applications for offline use cases are of importance. The patent if granted will be valid for 20 years until May 2044....

Omnämnda personer: applications for offline.

Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer

Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track

Sammanhang: ...FDA Fast Track Designation accelerates the approval process for Alpha 1H and potential for reaching the US market....

Omnämnda platser: Lund, Sweden. Omnämnda personer: Hamlet BioPharma, Hamlet BioPharma AB.

Crunchfish provides and patents Digital Cash privacy

Crunchfish released today an upgraded version of the Digital Cash SDK which enables privacy by design for offline payments in CBDC and commercial payment systems. In parallel, Crunchfish has applied for a patent for its innovative privacy feature, balancing

Sammanhang: ...Crunchfish released today an upgraded version of the Digital Cash SDK which enables privacy by design for offline payments in CBDC and commercial payment systems. In parallel, Crunchfish has applied for a patent for its innovative privacy feature, balancing privacy with regulatory requirements for transactional traceability. ...

Slutreplik: Sverige behöver en grön industripolitik

Sverige behöver en tydlig, grön industripolitik som gör det lättare för företag och investerare att våga satsa på klimatet, skriver Magnus Agerström, vd Cleantech for Nordics och Eva Andersson, Klimatanalytiker Cleantech for Nordics i en slutreplik.

Sammanhang: ...Sverige behöver en tydlig, grön industripolitik som gör det lättare för företag och investerare att våga satsa på klimatet, skriver Magnus Agerström, vd Cleantech for Nordics och Eva Andersson, Klimatanalytiker Cleantech for Nordics i en slutreplik....

Omnämnda platser: Sverige. Omnämnda personer: Eva Andersson, Magnus Agerström, Klimatanalytiker Cleantech for Nordics.

Crunchfish to perform security assessment for leading payment scheme

Crunchfish having world-leading expertise to deliver device agnostic trusted client applications has been engaged to conduct a security and vulnerability assessment for a prominent payment service. The assessment will be conducted during Q2 for a contract

Sammanhang: ...Crunchfish having world-leading expertise to deliver device agnostic trusted client applications has been engaged to conduct a security and vulnerability assessment for a prominent payment service. The assessment will be conducted during Q2 for a contract value of 325,000 SEK....

Omnämnda personer: applications has.

The Polygiene Group launches groundbreaking, plant-based technology for the textile market

The Polygiene Group launches a unique, plant-based antimicrobial technology for the textile market. Polygiene signed an exclusive distributor agreement with the French biotech company Proneem. The agreement runs for 3 years and gives Polygiene access to new,

Sammanhang: ...The agreement runs for 3 years and gives Polygiene access to new, innovative technology that will complement their existing portfolio of odor control solutions....

Omnämnda personer: Polygiene Group.

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was

Sammanhang: ...Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. ...

Omnämnda platser: Oslo, Navamedic.

Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed

Sammanhang: ...Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed for recruitment at the end of 2023, and patients are currently in long-term follow-up. ...

Omnämnda personer: Peritoneal Carcinomatoses Oncoinvent ASA.

Nitro Games signs Publishing agreement for Autogun Heroes

Nitro Games has signed a Publishing agreement (“Agreement”) for Autogun Heroes with publishing solution Supersonic from Unity (“Supersonic”).

Sammanhang: ...Nitro Games has signed a Publishing agreement (“Agreement”) for Autogun Heroes with publishing solution Supersonic from Unity (“Supersonic”)....

Omnämnda personer: Autogun Heroes, Nitro Games.

Antimicrobial peptide therapy for tuberculosis infections

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the tuberculosis project.

Sammanhang: ...Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the tuberculosis project. A PhD thesis entitled ‘’Antimicrobial peptide therapy for tuberculosis infections’’, from the group of Professor G. ...

Omnämnda personer: Professor G. Godaly, Hamlet BioPharma.